Vertex Pharmaceuticals
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
CEOReshma Kewalramani
CEOReshma Kewalramani
Employees6,100
Employees6,100
HeadquartersBoston, Massachusetts
HeadquartersBoston, Massachusetts
Founded1989
Founded1989
Employees6,100
Employees6,100
VRTX Key Statistics
Market cap129.15B
Market cap129.15B
Price-Earnings ratio-228.42
Price-Earnings ratio-228.42
Dividend yield—
Dividend yield—
Average volume1.49M
Average volume1.49M
High today$512.75
High today$512.75
Low today$488.00
Low today$488.00
Open price$493.66
Open price$493.66
Volume1.70M
Volume1.70M
52 Week high$519.88
52 Week high$519.88
52 Week low$377.85
52 Week low$377.85
VRTX News
Benzinga 7d
Vertex Newly Approved Pain Treatment Lands Higher Cost Tier 3 Placement In UnitedHealth's Optum Rx FormulariesIn January, the Food and Drug Administration (FDA) approved Vertex Pharmaceuticals Inc. VRTX Journavx, a non-opioid oral pain signal inhibitor for acute pain....
Simply Wall St 7d
Vertex Pharmaceuticals (NasdaqGS:VRTX) Gains UK Approval For New Cystic Fibrosis TreatmentOn March 7, 2025, announced that its cystic fibrosis treatment, ALYFTREK®, had received regulatory approval from the UK's MHRA, a significant milestone in expan...
Analyst ratings
57%
of 35 ratingsBuy
57.1%
Hold
37.1%
Sell
5.7%